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Abstract: Male hypogonadism is often treated by testosterone (T) replacement therapy such as oral
administration of the ester prodrug, testosterone undecanoate (TU). However, the systemic exposure
to T following oral TU is very low due to esterase-mediated metabolism, particularly in the small
intestine. The aim of this work was to examine the esterase-inhibitory effect of natural fruit extract of
strawberry (STW) on the intestinal degradation of TU as a potential approach to increasing the oral
bioavailability of T. Herein, the hydrolysis of TU was assessed in fasted state simulated intestinal
fluid with added esterase activity (FaSSIF/ES) and Caco-2 cell homogenates in the presence of STW
extract. It is noteworthy that STW substantially inhibited the degradation of TU in FaSSIF/ES and
Caco-2 cell homogenates at concentrations that could be achieved following oral consumption of
less than one serving of STW fruit. This can significantly increase the fraction of unhydrolyzed
TU in the intestinal lumen as well as in enterocytes. In addition, it was demonstrated that TU has
high intestinal lymphatic transport potential as the association of TU with plasma-derived human
chylomicrons was in the range of 84%. Therefore, oral co-administration of TU with STW could
potentially increase the intestinal stability of TU and consequently the contribution of lymphatically
delivered TU to the systemic exposure of T in vivo.
Keywords: testosterone undecanoate; FaSSIF; intestinal degradation; first-pass metabolism; strawberry
1. Introduction
Testosterone (T) is an essential androgen in the development of the male reproductive
system and sexual characteristics [1]. Inadequate release of testicular T is associated with
male hypogonadism, a clinical condition that affects the quality of life [2]. Symptomatic
hypogonadism is usually treated by T replacement therapy [3]. T is available as a trans-
dermal patch and gel, subdermal implants, buccal tablet, and nasal gel [3]. T is well
absorbed from the gastrointestinal tract. However, the extensive first-pass metabolism of
T limits its use as an orally effective therapeutic option in the treatment of hypogonadal
disorders [4]. The ester prodrug of T, testosterone undecanoate (TU), was approved as
an orally effective androgen [5]. TU is metabolised by non-specific plasma esterases to T
(Figure 1) [6]. It was demonstrated that TU increases systemic T exposure predominantly
by enhancing intestinal lymphatic transport, thus avoiding first-pass metabolism in the
liver [7–9], yet, the systemic exposure to T following oral administration of TU was less
than 7% in humans [10]. Several human and animal studies have revealed that a large
fraction of TU is metabolised in the intestinal lumen and intestinal wall. The metabolites,
primarily T, are absorbed via the portal vein to the liver where they are further extensively
metabolised. Moreover, the small fraction of TU that bypasses the intestine is metabolised
in the liver [7–9,11]. The uptake of TU by chylomicrons (CM) in enterocytes during the
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process of intestinal lymphatic transport was proposed as the primary pathway for the
bioavailable T. This pathway could reduce the fraction of TU being hydrolysed in the wall
of the intestines as well as in the liver [7,12]. We have recently suggested that decreasing the
intestinal metabolism of TU could be a valid approach to enhancing the oral bioavailability
of T as the intestinal wall, as opposed to the liver, is the site where around 90% of the
absorbed TU is metabolised [12].
Figure 1. Hydrolysis of testosterone undecanoate (TU) to testosterone.
In addition, it has been demonstrated that fruit extracts, particularly strawberry
(STW), can significantly inhibit the intestinal degradation of the esterase-sensitive antiviral
prodrug tenofovir disoproxil [13,14]. Therefore, the present study was designed to evaluate
the inhibitory effect of STW on the intestinal metabolism of TU as a strategy to increase the
availability of TU for intestinal lymphatic transport and hence the systemic exposure to T.
2. Materials and Methods
2.1. Materials
TU and Vitamin D3 were purchased from Beijing Sjar Technology Development (Bei-
jing, China) and Alfa Aesar (Lancashire, UK), respectively. Hank’s balanced salt solu-
tion (HBSS), 4-2-hydroxyethyl-1-piperazineethanesulfonic acid (HEPES) buffer, lecithin,
porcine liver esterase, FBS, sodium taurocholate (NaTc), NaH2PO4, NaCl, KBr, fast blue BB
salt (4-benzoylamino-2,5-dimethoxybenzenediazonium chloride hemi (zinc chloride) salt),
and gallic acid were obtained from Sigma (Gillingham, UK). Dulbecco’s modified Eagle
medium (DMEM) with added GlutaMAX™, D-glucose, and HEPES was procured from
Gibco (Paisley, UK).
2.2. Determination of Total Phenolics in STW
Phenolic compounds are important components of STW that have demonstrated
biological activities [15]. In this study, total phenolic contents were determined to estimate
the amount of fresh STW fruit that is equivalent to the amount of freeze-dried STW powder.
Phenolic contents (gallic acid equivalents) in freeze-dried STW powder and fresh STW
fruits were determined by fast blue BB assay according to the literature [16]. Briefly, freeze-
dried powder (0.25 g) and pieces of freshly cut STW fruit (2.5 g) were homogenised with
3 mL and 12 mL of 70% aqueous methanol (v/v), respectively, at 12,000 rpm for 30 s
(POLYTRON®, Luzern, Switzerland). Samples were then subjected to ultrasonication for
30 s followed by centrifugation (6650× g, 10 min, room temperature). Supernatants were
collected in new tubes and diluted in water (1:20; v/v). One-hundred and fifty microliter
of diluted samples, gallic acid standards, or water was placed in a flat and clear bottom
96-well plates. Fast blue BB solution (1%, 15 µL) was added and mixed for 30 s. Next,
an NaOH solution (1 M, 15 µL) was added and mixed for 30 s. Samples were incubated
for 90 min at room temperature, protected from light. Absorbance was then measured at
420 nm (EnVision® Multilabel Plate Reader, PerkinElmer Inc., Waltham, MA, USA). Total
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phenolic content was then determined as gallic acid equivalent based on a calibration cure
of gallic acid standards.
2.3. Stability of TU in Fasted State Simulated Intestinal Fluid with Added Esterase
Activity (FaSSIF/ES)
The stability of TU was assessed in fasted state simulated intestinal fluid with added
esterase activity (FaSSIF/ES; 20 IU/mL) in the presence of 0%, 2%, and 4% STW extract
(weight of freeze-dried STW powder per volume of the medium). FaSSIF was prepared
according to the literature [17]. The stability of TU in FaSSIF/ES was performed as de-
scribed in the literature [18,19]. The reaction medium (1 mL) was incubated at 37 ◦C for
5 min prior to the experiment. The reaction was then initiated by the addition of TU to
yield a concentration of 10 µM. Samples (100 µL each) were withdrawn at 0, 15, 30, 45, and
60 min. Three-hundred microliter of ice-cold acetonitrile (ACN) was immediately added to
the samples to stop the reaction. Later, samples were prepared for HPLC-UV analysis in
the same day as described below. In addition, TU stability was assessed in FaSSIF without
esterase to determine the chemical stability. The depletion rate constant of TU (k) was
obtained from the plot of logarithmic concentrations of TU (% of concentration at time 0)
versus time. The elimination half-life (t1/2) of TU depletion was then calculated according
to Equation (1). Experiments were performed in quadruplet.
t1/2 = 0.693/k (1)
2.4. Stability of TU in Caco-2 Cell Homogenates
The stability of TU was assessed in human intestinal Caco-2 cell homogenates in
the presence of 0%, 2%, and 4% STW extract. For ester prodrug stability studies, Caco-
2 cell homogenate was demonstrated as an equivalent alternative to human intestinal
homogenate [20] and has been applied to predict the first-pass metabolism of TU in the
small intestine [12]. The preparation of Caco-2 cell homogenate was described before [12].
Briefly, cells were seeded in culture flasks at a density of 3.75 × 104 cells/cm2. Cells were
maintained at 37 ◦C, 95% relative humidity, and 5% CO2 for 21 days. Then, confluent cells
were scraped and lysed by ultrasonication followed by centrifugation (10,000× g, 5 min,
4 ◦C) to obtain the supernatant. The concentration of proteins was adjusted to 1 mg/mL
for the stability study.
The stability of TU in Caco-2 cell homogenate was assessed as described before [12].
Briefly, cell homogenates (1 mL) were spiked with TU to obtain a concentration of 10 µM.
Homogenates were then incubated for 1 h at 37 ◦C with continuous shaking at 200 rpm.
Samples (100 µL each) were withdrawn at 0, 15, 30, 45, and 60 min. Three-hundred
microliter of ice-cold ACN was immediately added to the sample to stop the hydrolysis.
Later, samples were prepared for HPLC-UV analysis in the same day as described below.
Experiments were performed in quadruplet.
2.5. Assessment of Intestinal Lymphatic Transport Potential
The intestinal lymphatic transport potential of TU was evaluated by determining the
association of TU with plasma-derived human CM as previously described [21]. To note,
CM association is a key step in the intestinal lymphatic transport of drugs [21,22]. The
ethical approval for this experiment was obtained from the Faculty of Medicine and Health
Sciences Research Ethics Committee, Queens Medical Centre, Nottingham University
Hospitals (BT12102015 CBS SoP). Three healthy human males (25–40 years old) that had not
been on any medication one-week prior experiment were enrolled in this study. Following
overnight fasting, participants received a high-fat breakfast (full English breakfast or olive
oil-fried eggs). Thirty millilitres of blood samples were collected in heparinised tubes 3–4 h
after breakfast. Plasma was separated by centrifugation (800× g, 10 min, 15 ◦C). CM were
harvested from plasma using a density gradient technique [21]. Briefly, the density of
plasma aliquots was adjusted to 1.1 g/mL by KBr. Four millilitres of plasma were placed
in polyallomer ultracentrifuge tube and standard solutions of PBP with densities of 1.063,
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1.019, and 1.006 g/mL were layered on top. Following ultracentrifugation (268,350× g,
35 min, 15 ◦C; SORVALL® TH-641 Rotor, Thermo Fisher Scientific, Gloucester, UK), the
top 1 mL layer containing CM was carefully decanted. Triglyceride concertation in CM
emulsion was determined by triglycerides enzymatic kit according to the manufacturer
protocol (Sigma Aldrich, Dorset, UK) and adjusted to 100 mg/dL by dilution with standard
PBS solution (1.006 g/mL density). Pooled CM emulsion from all volunteers was stored in
the fridge at 4–8 ◦C until the uptake experiments (<24 h).
The uptake of TU by human CM emulsion was performed as described in the lit-
erature [22]. TU was spiked to 1 mL of CM emulsion in a test tube to achieve molar
concentration of 1.75 µM. Reaction tubes were incubated for 1 h at 37 ◦C with continuous
mixing. Following incubation, 900 µL of CM emulsion was transferred to a new tube and
the density was adjusted to 1.1 g/mL using KBr. CM were separated by ultracentrifugation
(268,350× g, 35 min, 15 ◦C; SORVALL® TH-641 Rotor, Thermo Fisher Scientific, UK). Fol-
lowing ultracentrifugation, the upper 1 mL layer was carefully decanted and processed for
HPLC-UV analysis on the same day, as described below. The concentration of TU was also
determined in CM emulsion prior to density gradient ultracentrifugation. The association
of TU with human CM was calculated according to Equation (2).
Association of TU with human CM (%) =
Amount of TU in CM emulsion following ultracentrifugation
Amount of TU in CM emulsion at the end of incubation
× 100 (2)
2.6. Analytical Methods
The determination of TU concentrations in FaSSIF, Caco-2 cell homogenates, and CM
emulsion was performed using Waters Alliance HPLC-UV system (Waters Corporation,
Milford, MA, USA) as previously described [12]. Concisely, 300 µL of ACN and 20 µL of
the internal standard (vit D3, 50 µm) were added to 100 µL of sample and vortexed for
1 min. Two-hundred microlitre of HPLC-grade water was added and vortexed for 1 min.
Three millilitres of n-Hexane were added followed by 10 min vortex-mixing for extraction.
Samples were then centrifuged (1160× g, 10 min, 15 ◦C) and the upper organic layer was
transferred to a new tube and evaporated under N2 stream. Samples were redissolved in
100 µL ACN and 20 µL was injected for HPLC-UV analysis.
Analytes were separated on ACE C18 (4.6 mm ID × 10 cm) column at 50 ◦C (Hichrom
Ltd., Reading, UK). The mobile phase was an isocratic mixture of ACN and water (96:04;
v/v). The flow rate was set at 0.5 mL/min and the absorbance was monitored at 240 nm for
20 min. EmpowerTM 2 software was used for data processing. The elution time of TU was
11.3 min. For FaSSIF and Caco-2 cell homogenate samples, analyte/internal standard peak
area ratios were determined and normalised to the value at time zero. For CM emulsion
samples, calibration curves were constructed and used to calculate TU concentration. The
analytical method was validated for selectivity, accuracy, and precision in accordance
with the FDA Guidance for Bioanalytical Method Validation [23]. The lower limit of
quantification was 0.2 µM. Inter- and intra-day precision and accuracy were below 15%
RSD and RE, respectively.
2.7. Statistical Analysis
The results are expressed as mean ± standard deviation (SD). The statistical signifi-
cance between data sets was analysed using ANOVA with Dunnett’s multiple comparisons
test. A p < 0.05 was considered statistically significant.
3. Results
3.1. Phenolic Contents in Freeze-Dried STW and Fresh STW Fruit
The determination of phenolic contents has demonstrated that each 10 g of freeze-
dried STW powder is equivalent to approximately 90 g of fresh STW fruit. Total phenolics
in freeze-dried STW powder were 0.67 ± 0.09 g (gallic acid equivalent in 10 g freeze-dried
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powder, n = 3). In fresh STW fruit, total phenolics were 0.76 ± 0.12 g (gallic acid equivalent
in 100 g fresh STW, n = 5).
3.2. Stability of TU in FaSSIF/ES
The stability of TU was tested in FaSSIF/ES to simulate physiological conditions in the
small intestine. The depletion of TU in the reaction medium corresponded to the hydrolysis
of TU by esterases. The hydrolysis of TU in FaSSIF/ES is shown in Figure 2a, which also
shows that TU is stable in simulated intestinal fluid without added esterase, indicating
chemical stability in FaSSIF over the incubation period (60 min). As shown in Figure 2b, the
hydrolysis of TU in the presence of esterase was substantially inhibited when co-incubated
with 2% and 4% STW extracts in a dose-dependent manner. The t1/2 depletion of TU in
FaSSIF/ES was 18.9 ± 1.6 min, which was increased 13-fold in the presence of 2% STW
extract. In the presence of 4% STW extract, TU was stable over the reaction time, and
therefore t1/2 depletion could not be calculated.
Figure 2. Stability of testosterone undecanoate (TU) in fasted state simulated intestinal fluid (FaSSIF) with esterase (ES)
activity (20 IU/mL) and without ES (a) and in the presence of 0%, 2%, and 4% strawberry (STW) extract (b). Values are
presented as a percentage of TU concentration at time 0 (mean ± SD, n = 4). Two-way ANOVA with Dunnett’s multiple
comparisons test was used for statistical analysis. Statistical differences compared to FaSSIF/ES group; *** p < 0.001;
**** p < 0.0001.
3.3. Stability of TU in Caco-2 Cell Homogenate
The stability of TU was tested in Caco-2 cell homogenate to assess the effect of STW
on the metabolic activity in the intestinal wall. The hydrolysis-time profiles of TU in Caco-2
cell homogenates in the presence of different concentrations of STW extract are shown in
Figure 3a. STW has significantly inhibited the hydrolysis of TU in Caco-2 cell homogenates
at the tested concentrations (2% and 4%). The unhydrolyzed fractions of TU dose at the
end of incubation are presented in Figure 3b.
3.4. Intestinal Lymphatic Transport Potential of TU
Affinity to CM is a prerequisite for efficient intestinal lymphatic transport [21,24],
which had earlier been demonstrated to be linearly proportional to the value of CM
association [22]. In this study, TU showed high association values with natural human CM
(84.3 ± 19.8%, mean ± SD, n = 5).
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Figure 3. (a) The hydrolysis of testosterone undecanoate (TU) in Caco-2 cell homogenates in the presence of 0%, 2%, and 4%
strawberry (STW) extract; (b) The unhydrolyzed fraction of TU dose following 60 min incubation. Values are expressed
as percentage of TU concentration at time 0 (mean ± SD, n = 4). Statistical analysis was performed using one-way and
two-way ANOVA with Dunnett’s multiple comparisons test, as appropriate. Statistical differences of 2% and 4% STW
groups were similar when compared to STW-free Caco-2 cell homogenate group; *** p < 0.001; **** p < 0.0001.
4. Discussion
T replacement therapy is often used to treat symptomatic hypogonadism in men.
Therapeutic levels of T can be achieved following oral administration of TU. However,
the systemic exposure to T following oral TU is very low due to substantial first-pass
metabolism, particularly in the small intestine [12]. Herein, we have evaluated the in-
hibitory effect of natural fruit extract of STW on the intestinal degradation of TU as a
potential approach to increasing the oral bioavailability of T.
In general, following oral administration, pre-systemic degradation of a prodrug in
the intestinal lumen could considerably decrease the fraction of dose available for systemic
absorption. For ester prodrugs, intestinal degradation could be due to chemical and/or
enzymatic hydrolysis [25]. Multiple hydrolysing enzymes are present in the lumen of
intestine, of which carboxylesterases are highly expressed [26]. In the current study, TU
was chemically stable over 60 min of incubation in physiologically simulated intestinal
fluid, FaSSIF (Figure 2a). However, the addition of esterase activity, which corresponds
to a mixture of esterases that include carboxylesterase, resulted in the rapid hydrolysis of
TU in FaSSIF with a depletion t1/2 of 18.9 min. Consequently, more than 90% of TU was
degraded within 60 min (Figure 2a). Therefore, it is estimated that a large proportion of the
administered dose could be degraded in the intestinal lumen. This can markedly decrease
the fraction of TU absorbed into the intestinal wall, thus reducing the bioavailability of T
following oral administration of TU in vivo.
In the presence of 2% freeze-dried STW, the hydrolysis of TU in FaSSIF/ES was sub-
stantially decreased, preserving more than 50% of TU from being hydrolysed by esterases
over the incubation period (Figure 2b). In addition, TU was almost completely preserved
from hydrolysis when co-incubated with 4% freeze-dried STW (Figure 2b). Therefore, STW
could significantly increase the fraction of TU available for absorption in the intestinal
lumen. As TU is a highly lipophilic molecule, the fraction available for absorption can
also be limited by the low solubility in the intestinal lumen. Thus, in addition to esterase
inhibition, formulation approaches could be applied to increase the fraction of TU available
for absorption into the intestinal lumen.
Experimental determination of phenolic content has demonstrated that oral intake
of 45 g and 90 g of fresh STW fruit can produce intestinal concentrations equivalent to 2%
and 4% of freeze-dried STW, respectively, assuming intestinal fluid volume of 250 mL. To
note, it is estimated that one serving of STW fruit is around 140 g [27]. Therefore, achieving
esterase-inhibitory concentrations in the intestinal lumen is highly likely following the
consumption of less than one serving of STW fruit. The esterase-inhibitory effect of STW
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could be attributed to the fact that STW is rich in multiple ester compounds, which could
competitively inhibit the hydrolysis of ester prodrugs [14].
Further, we used Caco-2 cell homogenates to assess the effect of STW on the intestinal
first-pass metabolism of TU. In fact, we previously applied the degradation of TU in Caco-2
cell homogenate to predict the fraction of TU that could escape intestinal metabolism, which
was as low as 11% of the absorbed fraction [12]. In this study, STW substantially altered the
depletion profile of TU in Caco-2 cell homogenates (p < 0.001; Figure 3a). At 2% freeze-dried
STW, the unhydrolyzed fraction of TU in Caco-2 cell homogenate increased to around 95%
compared with 69% in STW-free homogenate over 60 min incubation (Figure 3b). This can
potentially increase the fraction of TU that could survive metabolism in the intestinal wall
in vivo. As the intestinal wall is the main site for first-pass metabolic loss of TU relative
to the liver [12], it is anticipated that exposure to T could significantly be increased after
oral administration of TU. The presence of 2% STW, as illustrated in Figure 3b, almost
completely inhibited the degradation of TU, suggesting that ester compounds from STW
saturated the hydrolysing enzymes. Therefore, upon increasing the concentration of STW
to 4%, only a minor increase in the unhydrolyzed fraction of TU was observed.
As mentioned earlier, animal and human studies have shown that intestinal lym-
phatic transport of TU is the primary absorptive pathway for the majority of bioavailable
T after oral administration of TU [7–9,11]. In this study, we assessed the intestinal lym-
phatic transport potential of TU by measuring the association with plasma-derived human
CM. This approach was previously shown to provide accurate estimate for the intestinal
lymphatic transport of lipophilic compounds [18,21,28]. The high association value of
TU with CM in this study (84.3%) suggests considerable intestinal lymphatic transport
and improved bioavailability following oral administration in conditions that promote
CM assembly, particularly with long-chain triglyceride-rich lipids. The lipophilic drug
4,4′-dichlorodiphenyltrichloroethane (DDT) was reported to have comparable CM asso-
ciation value to TU (81.6%) [22]. Indeed, it was reported that around 22% of DDT dose
was transported to the intestinal lymphatic system following oral administration of DDT
with oleic acid in rats [29]. However, Coert et al. have shown that a low proportion of TU
dose, approximately 2%, was recovered in the intestinal lymphatics of rats following oral
administration with peanut oil [7]. Similarly, Shackleford et al. have demonstrated that
around 3% of a TU dose was delivered to the systemic circulation through the intestinal
lymphatics following oral administration of TU in dogs [8]. The authors suggested that
the metabolic degradation in enterocytes could decrease the fraction of intact TU available
for CM association. This is consistent with the metabolic profile of TU in Caco-2 cell
homogenate and the low predicted fraction of TU that could escape intestinal metabolism
as reported in our previous work (~11%) [12]. Therefore, the esterase-inhibitory effect of
STW could retain more unhydrolyzed TU in the intestinal lumen and enterocytes. This
means that more TU would be available for CM association and subsequent intestinal
lymphatic transport, thereby augmenting systemic exposure to T.
5. Conclusions
In conclusion, it is prudent to suggest that oral administration of TU with less than
one-serving of STW has the potential to decrease the hydrolysis of TU in the intestinal
lumen, as well as in the intestinal wall. Coupled with the high CM association, increasing
the unhydrolyzed fraction of TU in enterocytes could substantially increase the contribution
of lymphatically-delivered TU to the systemic exposure of T. While the data of the current
study are promising, further in vivo studies will be required to validate this approach as a
strategy to enhance the bioavailability of T following oral administration of TU.
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